FDA Orders Warning Pamphlet for Lotronex Due to Rare but Serious Side Effects

Strategic Insights -

The Food and Drug Administration has ordered a warning pamphlet to be attached to each bottle of Lotronex, a drug prescribed for women with irritable bowel syndrome, due to reports of rare but serious side effects. The decision, the first of its kind, came after 15 patients experienced severe side effects, including complications from severe constipation and ischemic colitis, with 10 being hospitalized and three requiring surgery. Although no deaths were reported, the potential risks associated with the drug have raised concerns among consumer groups, with the Public Citizen's Health Research Group calling for the drug to be withdrawn.

Key Takeaways:

  • Lotronex, a drug prescribed for women with irritable bowel syndrome, has been linked to rare but serious side effects, including complications from severe constipation and ischemic colitis.
  • The FDA has ordered a warning pamphlet to be attached to each bottle of the drug, making it the first time such a pamphlet has been required for any medication.
  • Since its approval in February, 15 patients have experienced severe side effects, with 10 being hospitalized and three requiring surgery.
  • The potential risks associated with the drug have raised concerns among consumer groups, with the Public Citizen's Health Research Group calling for the drug to be withdrawn.
  • The pamphlet warns patients not to start taking Lotronex if they suffer from constipation, to call their doctors if constipation occurs when taking the drug, and to stop taking it and call the doctor if they develop new or worsening abdominal pain or blood in their bowel movements.
  • The FDA is also ordering labeling changes and sending new information to doctors, warning them not to prescribe Lotronex for patients with Crohn's disease or ulcerative or ischemic colitis.
  • Lotronex was approved to treat only the diarrheal form of irritable bowel syndrome but has not shown significant benefit for all women it was intended for, with only 2 out of 10 patients experiencing a clear benefit.

Statistics:

  • 15 patients have experienced severe side effects since the approval of Lotronex in February.
  • 10 patients with severe side effects were hospitalized.
  • 3 patients required surgery due to complications from the drug.
  • More than 200,000 prescriptions have been written for Lotronex.
  • 2 out of 10 patients experienced a clear benefit from taking the drug.
  • 4 of 10 patients had no benefit from the drug.

Sources:

  • [1] New York Times, "F.D.A. Orders Warning Pamphlet for Drug with Severe Side Effects" (Exact date not provided)
  • [2] Glaxo Wellcome Inc. press release (Exact date not provided)
  • [3] FDA press release (Exact date not provided)
  • [4] Public Citizen's Health Research Group press release (Exact date not provided)